Pfizer And Boehringer Ingelheim Pharmaceuticals To Feature In Line Up At Extractables And Leachables USA Conference 7-9 May 2013, Providence, RI
Main Category: ConferencesArticle Date: 06 Feb 2013 - 9:00 PST
Pfizer And Boehringer Ingelheim Pharmaceuticals To Feature In Line Up At Extractables And Leachables USA Conference 7-9 May 2013, Providence, RI
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Extractables and Leachables USA 2013 (E&L USA) have released their full agenda for 2013. The 3 day event will feature a pre-conference workshop, poster sessions and a 2 day speaker program covering case studies on materials composition and quality, toxicological perspectives on E&Ls and challenges in E&L studies.
Smithers Rapra's annual Extractables and Leachables conferences attract a wide range of delegates. E&L USA 2012 was attended by an expanse of companies from pharmaceutical manufacturers, medical device manufacturers, packaging and materials suppliers to CROs, government and academia. Last year over 65 delegates visited the conference, the full list of attending companies can be found here.
E&L USA 2013 will cover the latest developments from industry practitioners and working groups to meet regulatory requirements and ensure compatibility in drug-package combinations. Speakers lined up include Dennis Jenke, Baxter Healthcare; Bill Beierschmitt, Pfizer, and Diane Paskiet, West Pharmaceutical Services.
Dan Norwood, Distinguished Research Fellow, Boehringer Ingelheim Pharmaceuticals, is one of the keynote speakers for E&L USA and scheduled to discuss the United States Pharmacopeia and the issue of leachables and extractables: past, present and future. On current challenges with respect to E&Ls, Norwood commented "the most significant current challenge for the entire pharmaceutical landscape is reaching consensus among all of the various stakeholders regarding how to address the key issues related to E&Ls for all drug product types and medical devices."
Further highlights of the conference include case studies from Johnson & Johnson, EMD Millipore and BD Medical on biodegradable and permanent implantable devices, single-use systems and elastomeric components for parenteral packaging. Plus the pre-conference workshop, led by Dr Andrew Feilden, Chemistry Operations Director and Sukhy Toot, Product Manager - Medical Devices at Smithers Rapra, will cover an introduction to extractables and leachables, material selection, risk based analysis and extractable and leachable testing. And, new for 2013, poster sessions will allow attendees to hear even more about recent research and findings relating to all areas of E&Ls.
For more information on E&L USA 2013 conference visit http://www.eandl-conference.com
To find out more information Smithers Rapra visit http://www.smithersrapra.com/
Contact
Smithers Rapra
Jo Martin
+44 (0)1372 802000
Jomartin@smithers.com
Visit our conferences section for the latest news on this subject.
MLA
20 Jun. 2013. <http://www.medicalnewstoday.com/releases/255990.php>
APA
http://www.medicalnewstoday.com/releases/255990.php.
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Pfizer And Boehringer Ingelheim Pharmaceuticals To Feature In Line Up At Extractables And Leachables USA Conference 7-9 May 2013, Providence, RI'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


